Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Peer

Showing results (51-60 of 181) with videos related to

Pageof 19
Sort By:
Current Opinion in Biotechnology|October 29, 2021
Principles for designing an optimal mRNA lipid nanoparticle vaccineEdo Kon, Uri Elia, Dan Peer
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2011
Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivoCharudharshini Srinivasan, Dan Peer, Motomu Shimaoka
Nature Biotechnology|November 13, 2021
RNA delivery with a human virus-like particleAnna Gutkin, Daniel Rosenblum, Dan Peer
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 11, 2023
Targeted nanomedicine: Lessons learned and future directionsNuphar Veiga, Yael Diesendruck, Dan Peer
Molecular and Cellular Therapies|June 10, 2015
Molecular and Cellular Therapies: New challenges and opportunitiesXiangdong Wang, Dan Peer, Bryon Petersen
Nature Biotechnology|March 30, 2023
CRISPR editing in the lung with novel lipidsUri Elia, Edo Kon, Dan Peer
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 7, 2026
cSMRTS for cancer therapeuticsSagi Ravid, Inbal Hazan-Halevy, Dan Peer
Methods in Molecular Biology (Clifton, N.J.)|September 13, 2011
Integrin-targeted nanoparticles for siRNA deliveryNoa Ben-Arie, Ranit Kedmi, Dan Peer
ACS Nano|October 14, 2011
Reshaping the future of nanopharmaceuticals: ad iudiciumS Moein Moghimi, Dan Peer, Robert Langer
Biomaterials|June 15, 2010
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activationRanit Kedmi, Noa Ben-Arie, Dan Peer
Pageof 19

Showing results (51-60 of 181) with videos related to

Sort By:
Pageof 19
Current Opinion in Biotechnology|October 29, 2021
Principles for designing an optimal mRNA lipid nanoparticle vaccineEdo Kon, Uri Elia, Dan Peer
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2011
Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivoCharudharshini Srinivasan, Dan Peer, Motomu Shimaoka
Nature Biotechnology|November 13, 2021
RNA delivery with a human virus-like particleAnna Gutkin, Daniel Rosenblum, Dan Peer
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 11, 2023
Targeted nanomedicine: Lessons learned and future directionsNuphar Veiga, Yael Diesendruck, Dan Peer
Molecular and Cellular Therapies|June 10, 2015
Molecular and Cellular Therapies: New challenges and opportunitiesXiangdong Wang, Dan Peer, Bryon Petersen
Nature Biotechnology|March 30, 2023
CRISPR editing in the lung with novel lipidsUri Elia, Edo Kon, Dan Peer
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 7, 2026
cSMRTS for cancer therapeuticsSagi Ravid, Inbal Hazan-Halevy, Dan Peer
Methods in Molecular Biology (Clifton, N.J.)|September 13, 2011
Integrin-targeted nanoparticles for siRNA deliveryNoa Ben-Arie, Ranit Kedmi, Dan Peer
ACS Nano|October 14, 2011
Reshaping the future of nanopharmaceuticals: ad iudiciumS Moein Moghimi, Dan Peer, Robert Langer
Biomaterials|June 15, 2010
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activationRanit Kedmi, Noa Ben-Arie, Dan Peer
Pageof 19